Bexicaserin, also known as LP352 and previously AN352 or E-3620, is a centrally acting, highly selective serotonin 5-HT2Creceptor agonist under investigation for neurological disorders such as developmental and epileptic encephalopathies (DEEs). It shows high binding affinity for 5-HT2C receptors (Ki≈ 13 nM) and demonstrates potent agonist activity (EC50 ≈ 3 nM), while maintaining >100-fold selectivity over 5-HT2Aand 5-HT2B receptors, minimizing the risk of hallucinations and cardiac valvulopathy. Preclinical studies have shown that Bexicaserin can reduce seizure burden and improve behavioral outcomes in rodent epilepsy models.
MedKoo Cat#: 140206
Name: Bexicaserin
CAS#: 2035818-24-5
Chemical Formula: C15H19F2N3O
Exact Mass: 295.1496
Molecular Weight: 295.33
Elemental Analysis: C, 61.00; H, 6.48; F, 12.87; N, 14.23; O, 5.42
The following data is based on the product molecular weight 295.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
